香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容 而引致的任何損失承擔任何責任。 Top Eminent Healthcare Group Limited （卓著健康集團有限公司 ）* （於開曼群島註冊成立之有限公司） （股份代號：6877） 有關收購TOP EMINENT II LIMITED的 主要交易及關連交易 獨立董事委員會及獨立股東之獨立財務顧問 收購目標公司 董事會欣然宣佈，於二零二六年二月二十六日（交易時段後），本公司（作為買方）與賣方（作為賣方） 訂立收購協議，據此，賣方已有條件同意出售，而本公司已有條件同意收購銷售股份（相當於目標公 司已發行股份的100%），代價為100,300,000港元。 合約安排 訂立收購協議前，外商獨資企業（目標公司的間接全資附屬公司）已與前海公司、銀川公司及登記股 東（視情況而定）訂立一系列結構性合約，以獲取合併聯屬實體的全部經濟利益及裨益。為合約安排 之目的，前海公司為銀川公司的直接境內控股公司，持有銀川公司100%股權，而銀川公司主要 ...

香港，二零二六年二月二十六日 （於開曼群島註冊成立之有限公司） （股份代號：6877） 董事會會議通知 Top Eminent Healthcare Group Limited（「本公司」）之董事（「董事」）會（「董事 會」）謹此公佈，董事會會議將於二零二六年三月十六日（星期一）舉行，藉以（其中 包括）批准本公司及其附屬公司截至二零二五年十二月三十一日止年度之全年業績及其 發佈，以及考慮建議派發末期股息（如有）。 承董事會命 Top Eminent Healthcare Group Limited 主席 姬廣飛 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Top Eminent Healthcare Group Limited （卓著健康集團有限公司）* 於本公告日期，董事會包括三名執行董事，即姬廣飛先生（主席兼行政總裁）、李江女士（副主席） 及張煥平先生；三名非執行董事，即李冏先生、袁峰先生及鍾卓勳先生；以及三名獨立非執行董事， 即周健男先生（ ...

Core Viewpoint - TE Healthcare (06877) anticipates a comprehensive loss attributable to shareholders of approximately HKD 7.1 million for the year ending December 31, 2025, following a projected comprehensive profit of approximately HKD 11.3 million for the year ending December 31, 2024 [1] Financial Performance - For the year ending December 31, 2025, the company expects to achieve other income of approximately HKD 4.6 million, a decrease of about 71% compared to other income of approximately HKD 16.3 million for the year ending December 31, 2024 [1] - The overall profitability of the company is negatively impacted by significant increases in administrative and operational expenses due to the expansion of B2C sales channels and digital marketing activities [1] Business Development - The company continues to expand its healthcare business and achieve growth in its B2C operations [1] - The anticipated loss for the year ending December 31, 2025, is also attributed to high professional and legal fees arising from specific corporate transactions and ongoing litigation matters [1]

Core Viewpoint - TE HEALTHCARE (06877) anticipates a net loss attributable to shareholders of approximately HKD 7.1 million for the year ending December 31, 2025, following a net profit of approximately HKD 11.3 million for the year ending December 31, 2024 [1] Financial Performance - For the year ending December 31, 2025, the company expects to achieve other income of approximately HKD 4.6 million, a decrease of about 71% compared to other income of approximately HKD 16.3 million for the year ending December 31, 2024 [1] - The anticipated loss for 2025 is attributed to significant increases in administrative and operational expenses due to the expansion of B2C sales channels and digital marketing activities [1] Business Operations - The company continues to expand its healthcare business and achieve growth in its B2C operations [1] - The overall profitability is negatively impacted by high professional and legal fees arising from specific corporate transactions and ongoing litigation matters [1]

Group 1 - The company TE HEALTHCARE (06877.HK) expects to report a net loss attributable to shareholders of approximately HKD 7.1 million for the year ending December 31, 2025, following a net profit of approximately HKD 11.3 million for the year ending December 31, 2024 [1] - The overall profitability of the company is negatively impacted by significant increases in administrative and operational expenses due to the expansion of B2C sales channels and digital marketing activities [1] - The company anticipates other income of approximately HKD 4.6 million for the year ending December 31, 2025, a decrease of about 71% compared to other income of approximately HKD 16.3 million for the year ending December 31, 2024, attributed to declines in foreign exchange gains and interest-related income [1] Group 2 - The board remains confident in the company's recovery and long-term development prospects, emphasizing the importance of strategic partnerships to enhance B2C growth momentum [2] - The company plans to optimize its product mix, explore new product and channel opportunities, strengthen cost control, streamline fulfillment and supply chain operations, and enhance operational controls [2] - As these measures are gradually implemented and non-recurring costs normalize, the board expects the company's financial performance to improve over time [2]

Top Eminent Healthcare Group Limited （卓著健康集團有限公司 ）* （於開曼群島註冊成立之有限公司） （股份代號：6877） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容 而引致的任何損失承擔任何責任。 內幕消息—盈利預警 本公告乃根據香港聯合交易所有限公司證券上市規則第13.09(2)(a)條（「上市規則」）及香港法例第571 章證券及期貨條例第XIVA部所載的內幕消息條文（定義見上市規則）作出。 股東及潛在投資者於買賣本公司證券時務請審慎行事，如有疑問應尋求專業意見。 Top Eminent Healthcare Group Limited（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）謹 此告知本公司股東（「股東」）及潛在投資者，根據對本集團截至二零二五年十二月三十一日止年度的未 經審核綜合管理賬目及董事會現時可得的其他資料與截至二零二四年十二月三十一日止年度的經審 核業績相比較所作出之初步評估，預期本集團截至二零二五年十 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 第 1 頁 共 10 頁 v 1.2.0 FF301 致：香港交易及結算所有限公司 公司名稱: Top Eminent Healthcare Group Limited （卓著健康集團有限公司）* 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06877 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.01 HKD | | 40,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 4,000 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: Top Eminent Healthcare Group Limited （卓著健康集團有限公司）* 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06877 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.01 HKD | | 40,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 4,000,000,000 | HKD | | 0.01 HK ...

Core Viewpoint - TE Healthcare (06877) announced the resignation of Mr. Zhou Zuyou from his positions as independent non-executive director, chairman of the remuneration committee, and member of the audit committee, corporate governance committee, and nomination committee, effective December 31, 2025. Mr. Zhou Jianan has been appointed as the independent non-executive director, chairman of the remuneration committee, and member of the audit committee, corporate governance committee, and nomination committee, effective January 1, 2026 [1]. Group 1 - Mr. Zhou Zuyou will focus on other business arrangements leading to his resignation [1] - Mr. Zhou Jianan's appointment fills the roles vacated by Mr. Zhou Zuyou [1] - The changes in the board structure will take effect at the end of 2025 and the beginning of 2026 [1]

Core Viewpoint - TE HEALTHCARE (06877) announced the resignation of Mr. Zhou Zuyou from his positions as independent non-executive director, chairman of the remuneration committee, and member of the audit committee, corporate governance committee, and nomination committee, effective December 31, 2025 [1] - Mr. Zhou Jiannan has been appointed as the independent non-executive director, chairman of the remuneration committee, and member of the audit committee, corporate governance committee, and nomination committee, effective January 1, 2026 [1] Group 1 - Mr. Zhou Zuyou will focus on other business arrangements leading to his resignation [1] - Mr. Zhou Jiannan's appointment fills the vacancy left by Mr. Zhou Zuyou [1]